Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H14N2.ClH |
Molecular Weight | 222.714 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C(C)C(CC2=CNC=N2)=CC=C1
InChI
InChIKey=OIWRDXKNDCJZSM-UHFFFAOYSA-N
InChI=1S/C12H14N2.ClH/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12;/h3-5,7-8H,6H2,1-2H3,(H,13,14);1H
Molecular Formula | C12H14N2 |
Molecular Weight | 186.253 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Detomodine hydrochloride is a sedative with analgesic properties and α2-adrenergic agonist The dose-dependent sedative and analgesic effects reduce production of excitatory neurotransmitters, thereby calming the horse, relieving abdominal pain, and facilitating bronchoscopy and other procedures. Currently, detomidine is only licensed for use in horses.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111338 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2984021 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Dormosedan Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Sedation and chemical restraint of deer. | 2002 Dec |
|
The effects of xylazine, detomidine, acepromazine and butorphanol on equine solid phase gastric emptying rate. | 2002 Jul |
|
N-Glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes. | 2002 Mar |
|
Epidural morphine and detomidine decreases postoperative hindlimb lameness in horses after bilateral stifle arthroscopy. | 2002 May-Jun |
|
Gait pattern of the ataxic horse compared to sedated and nonsedated horses. | 2006 Aug |
|
Effects of xylazine, medetomidine, detomidine, and diazepam on sedation, heart and respiratory rates, and cloacal temperature in rock partridges (Alectoris graeca). | 2006 Jun |
|
Electroencephalographic and electromyographic changes during the use of detomidine and detomidine-butorphanol combination in standing horses. | 2006 Mar |
|
Clinical observations surrounding an increased incidence of postanesthetic myopathy in halothane-anesthetized horses. | 2006 Mar |
|
The effect of hyoscine on dobutamine requirement in spontaneously breathing horses anaesthetized with halothane. | 2006 May |
|
Left- and right-sided laparoscopic-assisted nephrectomy in standing horses with unilateral renal disease. | 2007 Aug |
|
The use of alpha-2 agonists in the equine practice: comparison between three molecules. | 2007 Aug |
|
Radiographic closure time of appendicular growth plates in the Icelandic horse. | 2007 Jul 17 |
|
Caries in the infundibulum of the second upper premolar tooth in the horse. | 2007 Mar 28 |
|
Sedation with detomidine and acepromazine influences the endoscopic evaluation of laryngeal function in horses. | 2007 Nov |
|
A point mutation in a herpesvirus polymerase determines neuropathogenicity. | 2007 Nov |
|
The cardiopulmonary effects of etorphine, azaperone, detomidine, and butorphanol in field-anesthetized white rhinoceroses (Ceratotherium simum). | 2007 Sep |
|
Effects of dobutamine on cardiac index and arterial blood pressure in isoflurane-anaesthetized horses under clinical conditions. | 2009 Aug |
|
Vascular perfusion of reproductive organs in pony mares and heifers during sedation with detomidine or xylazine. | 2009 Jan |
|
Effect of detomidine on visceral and somatic nociception and duodenal motility in conscious adult horses. | 2009 Mar |
|
Total intravenous anesthesia with midazolam, ketamine, and xylazine or detomidine following induction with tiletamine, zolazepam, and xylazine in red deer (Cervus elaphus hippelaphus) undergoing surgery. | 2010 Oct |
Patents
Sample Use Guides
for horses:
Oral (gel): 0.04 mg/kg;
Intravenous or Intramuscular injection: 0.02-0.04 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9617754
The sedative alpha2-adrenoceptor agonists medetomidine and detomidine inhibited aldosterone release (range 10-1000 nM). The 4-substituted imidazoles atipamezole, detomidine, and medetomidine inhibited mitochondrial cytochrome P450(11beta/18) in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:00 GMT 2025
by
admin
on
Mon Mar 31 18:09:00 GMT 2025
|
Record UNII |
95K4LKB6QE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.536
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7048661
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
48928
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB11892MIG
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
95K4LKB6QE
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
C041255
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110829
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
Z-48
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
56031
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
DBSALT001711
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
100000076086
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
m4209
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
95K4LKB6QE
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
90038-01-0
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY | |||
|
C75038
Created by
admin on Mon Mar 31 18:09:00 GMT 2025 , Edited by admin on Mon Mar 31 18:09:00 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
SOLVATE->ANHYDROUS |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|